Monday, October 5, 2015

Optic Neuropathy Pipeline Review H2 2015 - 5 Companies & 11 Drug Profiles

. Buy Digestion Supplements online About Alfacip (Alfacalcidol) with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/nqk2jn/optic_neuropathy) has announced the addition of the "Optic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://cardiobloodreview.wordpress.com Buy Furadantin with no prescription About Benzoyl (Benzoyl Peroxide) with free Rx It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Garcinia Cambogia () Ventolin (Albuterol (Salbutamol)) with no prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Inotek Pharmaceuticals Corporation Neurotech Pharmaceuticals, Inc. PharmatrophiX, Inc. Quark Pharmaceuticals, Inc. Regenera Pharma Ltd. Drug Profiles Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy BA-240 NT-501 QPI-1007 RPh-201 Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy Small Molecules for CNS Disorders and Ophthalmology Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System Synthetic Peptide to Inhibit Connexin for Optic Neuropathy trabodenoson For more information visit .researchandmarkets.com/research/nqk2jn/optic_neuropathy

No comments:

Post a Comment